Humana Analysts Slash Their Forecasts After Q4 Results

Humana Inc. HUM reported fourth-quarter FY23 earnings and issued 2024 guidance on Thursday.

The company reported a Q4 adjusted loss of 11 cents per share, a turnaround from EPS income of $1.97 per share a year ago, missing the consensus for a loss of 5 cents per share. The insurer reported adjusted revenue of $25.73 billion, compared to $21.30 billion a year ago and the consensus of $25.55 billion, accoring to data from Benzinga Pro.

Humana announced its initial fiscal year 2024 EPS outlook of ‘approximately $14.87’ on a GAAP basis, ‘and approximately $16.00’ on an adjusted basis (versus consensus of $28.91).

Humana shares gained 2.5% to trade at $364.17 on Friday.

These analysts made changes to their price targets on Humana after the company reported quarterly results.

• Goldman Sachs cut the price target on Humana from $515 to $450. Goldman Sachs analyst Nathan Rich maintained a Buy rating.
• RBC Capital cut Humana price target from $507 to $415. RBC Capital analyst Ben Hendrix maintained an Outperform rating.
• UBS lowered the price target on Humana from $530 to $370. UBS analyst Kevin Caliendo downgraded the stock from Buy to Neutral.
• Stephens & Co. slashed the price target on Humana from $550 to $430. Stephens & Co. analyst Scott Fidel maintained an Overweight rating.

Now Read This: Bitcoin Tops $41,000 Following PCE Inflation Data; SATS Emerges As Top Gainer